ABSTRACT Aberrant DNA methylation has long been implicated in cancers. In this letter, we present a highly discriminative DNA methylation biomarker for non-small cell lung cancers (NSCLCs) and 14 other cancers. Based on 69 NSCLC cell lines and 257 cancer-free lung tissues, we identified a CpG island in SCT gene promoter, which was verified by qMSP experiment in 15 NSCLC cell lines and three immortalized human respiratory epithelium cells. In addition, we found that the SCT promoter was methylated in 23 cancer cell lines involving >10 cancer types profiled by ENCODE. We found that the SCT promoter is hypermethylated in primary tumors from TCGA lung cancer cohort. In addition, we found that SCT promoter is methylated at high frequencies in 15 malignancies and is not methylated in ∼1000 non-cancerous tissues across >30 organ types. This letter indicates that SCT promoter methylation is a highly discriminative biomarker for lung and many other cancers.
I. INTRODUCTION

M
ETHYLATION of the fifth position in the six atom carbon ring of the cytosine base (5 mC) is one of the best studied epigenetic modifications and is associated with development in mammals [1] . Due to the difference of biochemical properties between methylated cytosine and unmethylated cytosine, the methylated cytosine is sometimes called the ''fifth'' base [2] . DNA methylation occurs almost exclusively at CpG dinucleotide sites, although non-CpG methylation was recently found to be abundant in the stem cell genome [3] . Since the methylated cytosine may spontaneously deaminate to thymine, CpG sites are underrepresented in the human genome, possibly due to DNA methylation during evolution [4] . However, there are still stretches of DNA sequences with over-represented CpG sites, called CpG islands [5] . CpG islands are, in general, unmethy- Personal use is also permitted, but republication/redistribution requires IEEE permission. See http://www.ieee.org/publications_standards/publications/rights/index.html for more information. VOLUME 1, NO. 3, OCTOBER 2015 lated and overlap the promoter regions of 60%-70% of all human genes [5] . Moreover, the methylation status of cytosine nucleotides is somatically inheritable through maintenance methyltransferase (e.g., DNMT1), which mostly targets hemimethylated CpG dyads on the parental strand during DNA replication [6] . Lung cancer is the leading cause of cancer-related mortality worldwide, and many patients are usually diagnosed at advanced stages [7] . Five-year survival of lung cancer patients after resection strongly depends on tumor stages (67% for stage I versus 23% for stage IV), indicating the importance of early diagnosis [8] . Computed tomography (CT) screening is the most recent state-of-the-art method for early detection [9] . However, it is subject to high falsepositive rates [10] . As a result, confirming the presence of lung cancers by invasive biopsy is still a key step for early detection [10] . Molecular biomarkers offer great promise in early detection of lung cancers which in turn can reduce mortality. For example, DNA methylation has been studied in squamous cell lung cancer [11] and lung adenocarcinoma [12] - [14] , as well as multiple malignancies [15] . DNA methylation biomarkers for lung cancers are also studied in sputum [16] and plasma [17] for non-invasive procedures. In this report, we describe our search for a near universal lung cancer methylation marker, utilizing the vast amount of publically available data.
II. RESULT A. INITIAL SCREENING FOR HYPERMETHYLATED BIOMARKERS IN NON-SMALL CELL LUNG CANCER (NSCLC) CELL LINES
In order to discover DNA methylation markers for non-small cell lung cancers (NSCLCs), we obtained HumanMethylation450 (450k) methylation data for 69 cell lines (Table S1 ) derived from the tumors of NSCLC patients and 257 primary cancer-free lung tissues (Table S2 ). We applied t-test on the methylation M -values of the tumor and cancer-free samples for a search restricted on 390 920 CpG sites. We choose the CpG sites that are not within ten base pairs of known SNPs and are detectable in >95% cell lines. We considered probes with FDR level 1e-68 and effect size (i.e., differences of average M -values between cancer and non-malignant/normal samples) to be higher than +4.5 (a positive marker for tumors), and have at least two probes that are consistently hypermethylated in NSCLC cell lines ( Fig. S1-2) . The top two CGIs were chr11:626728-628037 overlapping with the promoter of secretin gene [SCT; Figs. S1-2 and 1(a), and Table S3 ] and chr2:63283936-63284147 overlapping with the 3'UTR of OTX1 (Table S3) . Here, we present the results on probe cg00249511 in the SCT promoter region in main figures. 1 1 The results of probe cg25774643 can be found in supplementary materials that can be accessed at http://biorxiv.org/content/early/2015 /08/05/018515. To check SCT methylation in other cancers, we obtained DNA methylation data in cell lines profiled by ENCODE (Table S1) , of which 23 cell lines were the cancer cell lines. As can be seen in Figs. 1(b) and S3-4, SCT promoter was methylated in all cancer cell lines, though its methylation level in cell lines BE2_C and SK_N_MC appears to be reduced. These data indicate that the SCT promoter might be a highly discriminative DNA methylation marker for lung and many other cancers.
B. VALIDATION OF SCT PROMOTER METHYLATION BY SCT-SPECIFIC qMSP
To validate the above findings, we developed an SCT-specific qMSP assay (Materials/Methods) by targeting the SCT pro- moter region and examined 15 NSCLC cancer cell lines and three immortalized human respiratory epithelial cell (HREC) lines, whose SCT methylation status was also confirmed by 450k methylation array (Table S4) . As can be seen in Figs. 2 and S5, the data from both methods consistently indicated the SCT promoter being methylated in lung cancer cell lines and none or minimal in those immortalized lung cell lines. In addition, the SCT qMSP analysis of normal WBC cells showed none or minimal level of SCT methylation, which was consistent with the SCT promoter bisulfite sequencing analysis (Zhang et al. manuscript in preparation).
C. SCT PROMOTER METHYLATION IN PRIMARY TUMORS AND NON-TUMOR SAMPLES
We next checked SCT promoter methylation in 30 cancer types and corresponding non-malignant samples (Table S5 ) profiled by TCGA [18] . As can be seen in Figs. 3 and S6 (top panel), the SCT promoter is methylated (mean β > 0.5) in a wide range of cancers, including ovarian, uterine/uterine corpus, cervical, lung, liver, bladder, esophageal, low grade glioma, prostate, head/neck, breast, kidney, and stomach, which involves 67.23% (5246/7803) patients in our analysis. Interestingly, the SCT promoter is also methylated, though at a reduced level and frequency, in cancers including diffuse large B-cell lymphoma, glioblastoma multiforme, mesothelioma, skin, sarcoma, pancreas, and kidney, which involves 18.65% (1455/7803) patients in our analysis. Finally, the SCT promoter does not seem to be highly methylated in cancers including colorectal, AML, testicular germ cell tumors, adrenocortical, rectum, kidney chromophobe, uveal melanoma, and thymoma, which involves 14.12% (1102/7803) patients in our analysis. The descriptive statistics of SCT promoter methylation in all cancer types are summarized in Table 1 .
Since the non-malignant tissues from TCGA demonstrated reduced but significant SCT promoter methylation [Figs. 3 and S6 (middle panel)], we collected the DNA methylation data from cancer-free samples (Table  S2) to account for possible field effect. As can be seen in Figs. 3 and S6 (bottom panel), it appears that the SCT promoter is not methylated in corresponding normal tissues/organs, though the sample sizes for a few tissue types are small. Moreover, the SCT promoter does not appear to be highly methylated in 98% samples from >30 tissue/organ types from cancer-free samples (Table S2 and Fig. S7) .
Based on the above data, we concluded that SCT promoter methylation is a highly discriminative biomarker for lung and 14 other cancers. Interestingly, the SCT gene does not appear to be expressed in the primary tumor and nonmalignant samples in our analysis (Table S6 ). In turn, we did not detect the SCT differential expression between tumor and non-malignant samples in our analysis (Fig. S8) .
III. DISCUSSION
In this report, we have discovered that SCT promoter methylation is a potential highly discriminative biomarker to separate the tumors from non-malignant tissues for lung and 14 other malignancies. Given the great discriminative potential of SCT promoter methylation in these 15 cancers, the applications for non-invasive procedures, such as detection in urine for bladder or renal cancers, sputum (or nasal mucosa as a surrogate marker) for lung cancer [19] , [20] , nipple aspirates for breast cancer, and prostatic massage for prostate cancer, may also be feasible. 
IV. MATERIALS AND METHODS
A. CELL LINES AND DNA
The 15 NSCLC lung cancer cell lines (Table S4) and three CDK4/hTERT-immortalized HREC lines (Table S4 ; [21] ) were provided by A. F. Gazdar and J. D. Minna (UT Southwestern Medical Center at Dallas), and the authenticity of these cell lines was confirmed by the DNA fingerprint genotyping tests. Genomic DNA was isolated using QIAamp Blood Mini kit (Qiagen). DNA concentrations were measured using Nanodrop2000 (Thermo Scientific).
B. SCT-SPECIFIC qMSP
The SCT-specific qMSP assay was designed to target the SCT promoter region and the first exon, and was performed similarly as described in [22] . The primers and probes sequences are available upon request. The qMSP PCR assay, including MYOD1 gene as an input DNA reference [22] , was carried out by LightCycler 480 system (Roche). CpGenome Universal Methylated DNA (Millipore) was used as positive control and methylated reference. The level of SCT methylation of a given test was presented as a percent of methylated reference (PMR) as determined by the method as described similarly in [22] and [23] . The methylation status of SCT in these lung cancer cell lines and HREC lines was also confirmed by Illumina HumanMethylation450 BeadChip (Illumina, San Diego, CA).
